News & Events

Billerica, MA -- Thursday, May 14, 2009 --

BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today the launch of the BD UltraPool™ HLM 150 reagent that consists of human liver microsomes (HLM) for use in in vitro ADME (absorption, distribution, metabolism, and excretion) drug discovery screening and development.

"BD Biosciences is committed to addressing the needs of pharmaceutical researchers," said Charles Crespi, Ph.D., Vice President of Discovery Biologicals, BD Biosciences. "This new reagent will allow scientists to maintain consistent, high-quality results in their assays and avoid the arduous task of qualifying new lots of reagents."

Cytochromes P450 (CYPs) are key drug metabolizing enzymes. However, CYP expression among individuals is highly variable. When performing ADME assays, it is critical to minimize the variability due to reagents in order to observe the difference in performance among drug candidates. BD UltraPool™ HLM 150 was developed to offer researchers a high degree of lot-to-lot consistency for CYP enzyme activity.

The BD UltraPool HLM 150 reagent helps ensure reliability in experimental results in multi-site and multi-year programs by delivering reproducible data across multiple drug-metabolizing enzymes when compared with reagents prepared from smaller pools of donors and/or prepared to lower standards. It also gives researchers access to a large donor pool (150) with equal gender mix, providing the best available representation of an "average individual’s" drug metabolism activity. The large donor pool is manufactured in large lot sizes that support multi-year drug discovery programs.

The BD UltraPool HLM 150 reagent is intended for research use only and not for use in diagnostic or therapeutic procedures. For more information please visit: www.bdbiosciences.com/admetox.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit http://www.bd.com.